Emily Rapalino is a highly accomplished intellectual property litigator who brings a blend of scientific expertise and courtroom experience to complex life sciences industry disputes. A partner in Goodwin’s IP Litigation practice and a member of the firm’s Life Sciences Disputes team, she draws on advanced degrees in biology to navigate the scientific and technical nuances at the heart of pharmaceutical and biotechnology litigation. Emily played a key role in the trial win for Cephalon involving Treanda®, an oncology drug with annual sales reaching up to $800 million, where the court found in Cephalon’s favor on all asserted infringement claims. She also secured key victories for Teva in the Eloxatin® patent disputes, helping win summary judgment of non-infringement and for Sandoz in the Esbriet® patent dispute, allowing Sandoz to be first to market with its generic product. She advises clients on a broad range of pre-litigation and litigation matters, relying on her deep industry knowledge to secure the best business outcomes for her clients.